<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="043665e5-c6e0-4353-9933-6ba9e4860842"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Flurbiprofen Sodium<br/>Ophthalmic Solution, USP 0.03% </title>
   <effectiveTime value="20111213"/>
   <setId root="043665e5-c6e0-4353-9933-6ba9e4860842"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="118802834" root="1.3.6.1.4.1.519.1"/>
            <name>Rebel Distributors Corp</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="118802834" root="1.3.6.1.4.1.519.1"/>
                        <name>Rebel Distributors Corp</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RELABEL"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="c9564737-de4c-4e07-8dfa-5dc52bfaead9"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20110602"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="42254-023"/>
                        <name>FLURBIPROFEN SODIUM</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>flurbiprofen sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="60758-910" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="0.3" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Z5B97MU9K4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>flurbiprofen sodium</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5GRO578KLP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>flurbiprofen</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2225PI3MOV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>thimerosal</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>citric acid monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>edetate disodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polyvinyl alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>potassium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium citrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydrochloric acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="2.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1">
                                       <translation code="C48477" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                                    </numerator>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="42254-023-25" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019404" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19970529"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_651266ce-371f-433a-9e81-3044c6f9e2ad">
               <id root="8c9bc70a-e6d5-4547-879c-a9893b68a841"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Sterile </paragraph>
               </text>
               <effectiveTime value="20110602"/>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_bbc4dd4d-9467-46a1-8520-5e298392c792">
               <id root="9e4e227c-d67b-4d90-a94e-1bb6574f0634"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION </title>
               <text>
                  <paragraph>Flurbiprofen sodium ophthalmic solution, USP 0.03% is a sterile topical nonsteroidal anti-inflammatory product for ophthalmic use. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Chemical Name:</content> Sodium (±)-2-(2-fluoro-4-biphenylyl)-propionate dihydrate. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Structural Formula:</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="id_681b40a2-443b-49e7-bde3-eeab8abd2d6b"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Contains: Active:</content> flurbiprofen sodium 0.03% (0.3mg/mL). </paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative:</content> thimerosal 0.005%. <content styleCode="bold">Inactives:</content> citric acid; edetate disodium; polyvinyl alcohol 1.4%; potassium chloride; purified water; sodium chloride; and sodium citrate. May also contain hydrochloric acid and/or sodium hydroxide to adjust the pH. The pH of flurbiprofen sodium ophthalmic solution 0.03% is 6.0 to 7.0. It has an osmolality of 260 - 330 mOsm/kg. </paragraph>
               </text>
               <effectiveTime value="20110602"/>
               <component>
                  <observationMedia ID="id_681b40a2-443b-49e7-bde3-eeab8abd2d6b">
                     <text>Structural Formula </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="043665e5-c6e0-4353-9933-6ba9e4860842-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_b8f1759f-e7cb-4013-8803-f2dfb54bd189">
               <id root="bc2ce1e7-b55a-4691-a3a3-9aa994d6f548"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY </title>
               <text>
                  <paragraph>Flurbiprofen sodium is one of a series of phenylalkanoic acids that have shown analgesic, antipyretic, and anti-inflammatory activity in animal inflammatory diseases. Its mechanism of action is believed to be through inhibition of the cyclo-oxygenase enzyme that is essential in the biosynthesis of prostaglandins. </paragraph>
                  <paragraph>Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed on animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilatation, increased vascular permeability, leukocytosis, and increased intraocular pressure. </paragraph>
                  <paragraph>Prostaglandins also appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms. In clinical studies, flurbiprofen sodium ophthalmic solution 0.03% has been shown to inhibit the miosis induced during the course of cataract surgery. Results from clinical studies indicate that flurbiprofen sodium has no significant effect upon intraocular pressure. </paragraph>
               </text>
               <effectiveTime value="20110602"/>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_d7c7ba94-adf5-4f43-b13b-7dea69e5f4bc">
               <id root="91e0025a-dae1-4951-a5ba-ac0f8f164780"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Flurbiprofen sodium ophthalmic solution 0.03% is indicated for the inhibition of intraoperative miosis. </paragraph>
               </text>
               <effectiveTime value="20110602"/>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_7cdf0edb-f9ad-4f2d-9d00-b3db6df1a301">
               <id root="79a5c2b2-a2d2-43c0-8b29-3dc39d1d2a07"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Flurbiprofen sodium ophthalmic solution 0.03% is contraindicated in individuals who are hypersensitive to any components of the medication. </paragraph>
               </text>
               <effectiveTime value="20110602"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_id_06fd54f4-d97f-498d-9450-946acfc66c8c">
               <id root="ab32ae89-a8bc-4d5a-942e-136d7950b08c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34071-1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS </title>
               <text>
                  <paragraph>With nonsteroidal anti-inflammatory drugs, there exists the potential for increased bleeding due to interference with thrombocyte aggregation. There have been reports that flurbiprofen sodium ophthalmic solution 0.03% may cause increased bleeding of ocular tissues including hyphemas in conjunction with ocular surgery. </paragraph>
                  <paragraph>There exists the potential for cross-sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs. </paragraph>
               </text>
               <effectiveTime value="20110602"/>
            </section>
         </component>
         <component>
            <section ID="i4i_precautions_id_edfb51c8-56de-494a-b497-502643dc4c88">
               <id root="c1b6fd30-9429-44a4-9410-e4f6be64fbe1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42232-9" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS </title>
               <effectiveTime value="20110602"/>
               <component>
                  <section ID="i4i_precautions_general_id_ad8408ab-a3ac-4168-9093-d97127c15823">
                     <id root="73f8e0d8-ea28-45bd-939c-c7260894dc7d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34072-9" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">General:</content> Wound healing may be delayed with the use of flurbiprofen sodium ophthalmic solution 0.03%. </paragraph>
                        <paragraph>It is recommended that flurbiprofen sodium ophthalmic solution 0.03% be used with caution in surgical patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. </paragraph>
                     </text>
                     <effectiveTime value="20110602"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_interactions_id_75357b0a-d199-49ec-b905-ce09408d7835">
                     <id root="bff2cb92-4a74-4577-a138-10213e65dc32"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Drug interactions:</content> Interaction of flurbiprofen sodium ophthalmic solution 0.03% with other topical ophthalmic medications has not been fully investigated. </paragraph>
                        <paragraph>Although clinical studies with acetylcholine chloride and animal studies with acetylcholine chloride or carbachol revealed no interference, and there is no known pharmacological basis for an interaction, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with flurbiprofen sodium ophthalmic solution 0.03%. </paragraph>
                     </text>
                     <effectiveTime value="20110602"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_70e4571d-0d0b-41e7-a657-e83ce6f9fbcd">
                     <id root="6cc1058c-b081-4b02-b1b8-ae4b61b50e5f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of fertility:</content> Long-term studies in mice and/or rats have shown no evidence of carcinogenicity with flurbiprofen. Long-term mutagenicity studies in animals have not been performed. </paragraph>
                     </text>
                     <effectiveTime value="20110602"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pregnancy_id_daac6f9a-fdfc-4080-b65b-d222482be8d5">
                     <id root="d935d6bb-f926-40e0-b379-7e55716f8809"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pregnancy:</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20110602"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_1fe54888-c389-46c6-9731-9702da436cf8">
                     <id root="dd68742e-bb4c-4479-8d2d-0423f6d05e2a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pregnancy category C.</content> Flurbiprofen has been shown to be embryocidal, delay parturition, prolong gestation, reduce weight, and/or slightly retard growth of fetuses when given to rats in daily oral doses of 0.4 mg/kg (approximately 333 times the human daily topical dose) and above. </paragraph>
                     </text>
                     <effectiveTime value="20110602"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_e8655707-83d9-4706-995a-e055b544d1bd">
                     <id root="1529c4e5-02e7-4e1f-b203-7f03e1dc3a4e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34080-2" displayName="NURSING MOTHERS SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Nursing mothers:</content> It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from flurbiprofen sodium, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </paragraph>
                     </text>
                     <effectiveTime value="20110602"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_f0461ace-d33f-4c6a-bb5c-3bf8ba223542">
                     <id root="06b44b0d-17ff-4947-9f63-f1fbccc3b05d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pediatric use:</content> Safety and effectiveness in pediatric patients have not been established. </paragraph>
                     </text>
                     <effectiveTime value="20110602"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_49620035-5deb-4881-beab-16a900dfc6cb">
                     <id root="a6962f0b-9f5c-48a3-8119-99a27ca172b7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Geriatric use:</content> No overall differences in safety or effectiveness have been observed between elderly and younger patients. </paragraph>
                     </text>
                     <effectiveTime value="20110602"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_4910e54f-3f53-4c8e-9145-10bd2860c516">
               <id root="562cf031-e1f4-42b7-ba34-e883f9a624c7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS </title>
               <text>
                  <paragraph>Transient burning and stinging upon instillation and other minor symptoms of ocular irritation have been reported with the use of flurbiprofen sodium ophthalmic solution 0.03%. Other adverse reactions reported with the use of flurbiprofen sodium ophthalmic solution 0.03% include: fibrosis, miosis, and mydriasis. </paragraph>
                  <paragraph>Increased bleeding tendency of ocular tissues in conjunction with ocular surgery has also been reported. </paragraph>
               </text>
               <effectiveTime value="20110602"/>
            </section>
         </component>
         <component>
            <section ID="i4i_overdosage_id_8af39120-24bd-419f-842a-10fb974384f1">
               <id root="780b9064-15bf-4e37-8fa4-2464d37729f5"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE </title>
               <text>
                  <paragraph>Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute. </paragraph>
               </text>
               <effectiveTime value="20110602"/>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_423c8c6d-48eb-49e1-bd4a-ec4926c63d48">
               <id root="009a8f46-e5aa-4cef-89c8-58cedfdf40a8"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION </title>
               <text>
                  <paragraph>A total of four (4) drops of flurbiprofen sodium ophthalmic solution 0.03% should be administered by instilling one (1) drop approximately every 1/2 hour beginning 2 hours before surgery. </paragraph>
               </text>
               <effectiveTime value="20110602"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_0a752cd9-8064-49da-bd5d-bdcd4c89ed5a">
               <id root="d5e455b8-aee3-4a48-a311-778b39f3fc5f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED </title>
               <text>
                  <paragraph>Flurbiprofen sodium ophthalmic solution, USP is available for topical ophthalmic administration as a 0.03% sterile solution, and is supplied in a white opaque low density polyethylene bottle with a controlled dropper tip and a gray high impact polystyrene cap in the following size: </paragraph>
                  <paragraph>2.5 mL in 5 mL bottle - NDC 42254-023-25 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Note:</content> Store at 15°-25°C (59°-77°F). </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>Revised January 2004 </paragraph>
                  <paragraph>© 2004 PACIFIC PHARMA<br/>Irvine, CA 92612, U.S.A. </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="id_8209b4bf-61e1-4017-bb79-5c04e89064de"/>
                  </paragraph>
                  <paragraph>71587PY11P </paragraph>
                  <paragraph>Relabeled by:</paragraph>
                  <paragraph>Rebel Distributors Corp</paragraph>
                  <paragraph>Thousand Oaks, CA 91320</paragraph>
               </text>
               <effectiveTime value="20110602"/>
               <component>
                  <observationMedia ID="id_8209b4bf-61e1-4017-bb79-5c04e89064de">
                     <text>Pacific Pharma Logo </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="043665e5-c6e0-4353-9933-6ba9e4860842-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_Principal_display_panel_id_0692ed4e-259c-46b1-92ec-17dfccffde4b">
               <id root="4e7e85da-a845-46c1-8554-1c85523b6fa8"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel</title>
               <text>
                  <renderMultiMedia referencedObject="id_0db7ecfa-866b-4979-891e-223533a35744"/>
               </text>
               <effectiveTime value="20110602"/>
               <component>
                  <observationMedia ID="id_0db7ecfa-866b-4979-891e-223533a35744">
                     <text>Flurbiprofen Sodium 0.03%</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="043665e5-c6e0-4353-9933-6ba9e4860842-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>